title: [Corneal allograft rejection: topical treatment vs. pulsed intravenous methylprednisolone - ten years' result].
abstract: OBJECTIVE
  To evaluate the efficacy of intravenous 500 mg methylprednisolone in addition to topical treatment with 1% prednisolone in the treatment of the first episode of corneal endothelial rejection in patients that were submitted to corneal allograft transplantation.
  
  
  METHODS
  Retrospective case-control study with 81 patients that presented the first episode of corneal endothelial rejection and were treated within the first 15 days of the onset of symptoms.
  
  
  RESULTS
  67 patients were treated with 1% topical prednisolone acetate and pulsed intravenous methylprednisolone 500 mg at the diagnosis of corneal allograft rejection. Fourteen patients were submitted to topical treatment only, thus forming the control group. Forty-one of 67 patients (61.2%) that were submitted to pulsed steroid had good outcome and 26 (38.8%) presented corneal graft failure while only 4 of 14 patients (28.57%) that received only topical steroids evolved with clear grafts and the remaining 10 patients (71.43%) with graft failure. Chi-square showed statistically significant association (p<0.05) to greater success with pulsed methylprednisolone.
  
  
  CONCLUSIONS
  This study suggests that the use of 500 mg intravenous methylprednisolone in addition to 1% topical prednisolone acetate for the treatment of endothelial corneal allograft rejection presents better outcomes in reverting corneal allograft rejection when compared to isolated use of 1% topical prednisolone acetate.
authors.affiliation: Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brasil. daciocosta@hotmail.com
authors.forename: Dácio Carvalho
authors.initials: DC
authors.lastname: Costa
authors.forename: Rosane Silvestre de
authors.initials: RS
authors.lastname: Castro
authors.forename: Mariela Soares Ferraz de
authors.initials: MS
authors.lastname: Camargo
authors.forename: Newton
authors.initials: N
authors.lastname: Kara-José
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D016022:Case-Control Studies; D016039:Corneal Transplantation; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; C009935:prednisolone acetate; D011239:Prednisolone; D008775:Methylprednisolone